期刊文献+

可注射硫酸钙/羟基磷灰石复合物作为经皮椎体成形术填充物的实验研究 被引量:4

Experimental study on injectable calcium sulphate and hydroxyapatite compounding as implant in Percutaneous Vertebroplasty
下载PDF
导出
摘要 目的探讨椎体成形术的有效填充材料。方法采用PVP技术将40%可注射硫酸钙/羟基磷灰石(CSH/HA)复合物注入实验兔L6椎体内,L5椎体作为对照,于术后2、4、6、8、10、12周行影像学、组织学观察及骨组织计量学测定。结果影像学显示:术后4周实验椎体填充区密度明显高于周围松质骨密度,术后10~12周实验椎体填充区密度与周围松质骨一致。不脱钙骨组织学检查显示:术后4周复合物降解不明显,已出现成骨效应,6周实验椎体填充区内材料明显降解及出现新生骨小梁,8周实验椎体缺损边缘和中心部分的骨小梁逐渐成熟,10~12周椎体缺损已完全修复,为成熟的骨小梁组织所填充。骨组织计量学测定显示:术后10~12周实验椎体填充区骨小梁百分比及厚度与周围松质骨无显著差异。结论40%CSH/HA复合物在实验动物椎体内降解时间合适,成骨效应良好,新骨形成质量好,能有效修复椎体缺损,因而可能是一种理想的PVP填充物。 Objective To study the effective injectable implant for percutaneous vertebroplasty(PVP). Methods 40% Injectable calcium sulphate and hydroxyapatite compounding was injected into rabbit L6 vertebral bodies through PVP tech- nique with L5 vertebral bodies as control. 2,4, 6, 8, 10, 12 weeks after injection radiological and histological and bone histomorphometric examination were performed. Results Radiological examination showed that 4 weeks after injection density of injected area is higher than adjacent cancellous bone. 10 - 12 weeks after injection density of injected area is the same as adjacent cancellous bone. Undecalcified histological examination showed that 4 weeks after injection compo- unding degraded less with obvious bone formation effects. 6 weeks after injection obvious material degradation and new trabecular bone was observed in L6 vertebral body defect area. 8 weeks after injection new trabecular bone in the center and at the edge of defect area began to mature. 10 - 12 weeks after injection the defect area was fully repaired with mature trabeculae. Bone histomorphometric examination showed that 10 - 12 weeks after injection there was no significant difference in trabecular area and thickness between defect and adjacent cancellous bone. Conclusion 40% injectable calcium sulphate and hydroxyapatite compounding in rabbit vertebral bodies has suitable degradation time and good bone formation effect, and can repair vertebral body defect effectively with new formed good quality trabeculae. Thus it may be an ideal implant in Percutaneous Vertebroplasty.
出处 《生物骨科材料与临床研究》 CAS 2010年第1期1-5,共5页 Orthopaedic Biomechanics Materials and Clinical Study
关键词 经皮椎体成形术 硫酸钙 羟基磷灰石 Percutaneous Vertebroplasty Injectable calcium sulphate Hydroxyapatite
  • 相关文献

参考文献7

二级参考文献36

  • 1刘宏建,陈勇,杜靖远,梁惠民,刘昌胜,汪岚.复合rhBMP-2的注射型磷酸钙人工骨在椎体成形术中的应用及生物力学评价[J].中华物理医学与康复杂志,2004,26(7):392-395. 被引量:8
  • 2刘宏建,杜靖远,韩松辉,梁惠民,刘昌盛.经皮椎体成形术治疗疼痛性骨质疏松性胸腰椎压缩骨折[J].华中科技大学学报(医学版),2004,33(4):481-484. 被引量:10
  • 3刘宏建,杜靖远,刘辉,韩松辉,王锐.绝经后骨质疏松症山羊模型的建立及其意义[J].中华实验外科杂志,2005,22(10):1266-1267. 被引量:18
  • 4[1]Mathis JM, Barr JD, Belkoff SM, et al. Percutaneous vertebroplasty: a developing standard of care for vertebral compression fractures. Am J Neuroradiol, 2001,22:373 - 381
  • 5[2]Zoarski GH, Snow P, Olan W J, et al. Percutaneous vertebroplasty for osteoporotic compression fractures: quantitative prospective evaluation of long-term outcomes. J Vasc Interv Radiol, 2002, 13:139 - 148
  • 6[4]Kaufmann TJ, Jensen ME, Ford G, et al.Cardiovascular effects of polymethylmethacrylate use in percutaneous vertebroplasty. Am J Neuroradiol, 2002, 23: 601 - 604
  • 7[5]Dahl OE, Garvik LJ, Lyberg TL.Toxic effects of methylmethacrylate monomer on leukocytes and endothelial cells in vitro. Acta Orthop Scand, 1994, 65: 147- 153
  • 8[6]Lim TH, Brebach GT, Renner SM, et al.Biomechanical evaluation of an injectable calcium phosphate cement for vertebroplasty. Spine, 2002, 27: 1297- 1302
  • 9RANDOLPH DA,NEGRI JL,DEVINE TR,et al.Controlled Dissolution Pellet Containing Calcium Sulfate[P].USP(S5614206),1997.
  • 10NILSSON M,FERNANDEZ E,SARDA S,et al.Characterization of A Novel Calcium Phosphate-sulphate Bone Cement[J].J Biomed Mater Res(S0021-9304),2002,61(4):600-606.

共引文献12

同被引文献30

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部